Molecular Targeted Approaches in Mantle Cell Lymphoma

Seminars in Hematology

Volumn 48, Issue 3, 2011, Pages 214-226

  Weniger, Marc A ^a   Wiestner, Adrian ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; AT 7519; B LYMPHOCYTE RECEPTOR; BH3 PROTEIN; BORTEZOMIB; BRUTON TYROSINE KINASE INHIBITOR; CAL 101; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; DINACICLIB; ENZASTAURIN; ENZYME INHIBITOR; FLAVOPIRIDOL; FOSTAMATINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; LYSINE DEACETYLASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MK 4827; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PCI 32765; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

ARTICLE; B LYMPHOCYTE; CANCER RELAPSE; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; HUMAN; MANTLE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; SURVIVAL;

CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOMA, MANTLE-CELL; MOLECULAR TARGETED THERAPY;

EID: 79960506526     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.05.001     Document Type: Article

References (100)

1. Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006, 6:714-727.
2. Smith M.R. Should there be a standard therapy for mantle cell lymphoma?. Future Oncol 2011, 7:227-237.
3. Dreyling M., Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematol Am Soc Hematol Educ Program 2009, 542-551.
4. Rosenwald A., Wright G., Wiestner A., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
5. Jares P., Colomer D., Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7:750-762.
6. Perez-Galan P., Dreyling M., Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011, 117:26-38.
7. Wiestner A., Tehrani M., Chiorazzi M., et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 2007, 109:4599-4606.
8. Klier M., Anastasov N., Hermann A., et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008, 22:2097-2105.
9. Lapenna S., Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009, 8:547-566.
10. Kouroukis C.T., Belch A., Crump M., et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:1740-1745.
11. Byrd J.C., Lin T.S., Dalton J.T., et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007, 109:399-404.
12. Lin T.S., Blum K.A., Fischer D.B., et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010, 28:418-423.
13. Manohar S.M., Rathos M.J., Sonawane V., Rao S.V., Joshi K.S. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res 2011, 35:821-830.
14. Santo L., Vallet S., Hideshima T., et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 2010, 29:2325-2336.
15. Squires M.S., Cooke L., Lock V., et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther 2010, 9:920-928.
16. Marzec M., Kasprzycka M., Lai R., et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006, 108:1744-1750.
17. Menu E., Garcia J., Huang X., et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res 2008, 68:5519-5523.
18. Janes M.R., Limon J.J., So L., et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010, 16:205-213.
19. Witzig T.E., Geyer S.M., Ghobrial I., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005, 23:5347-5356.
20. Ansell S.M., Inwards D.J., Rowland K.M., et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008, 113:508-514.
21. Hess G., Herbrecht R., Romaguera J., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27:3822-3829.
22. O'Connor O.A., Popplewell L., Winter J.N., et al. PILLAR-1: Preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to Bortezomib. Blood (ASH Annual Meeting Abstracts) 2010, 116:3963.
23. Renner C., Zinzani P.L., Gressin R., et al. A multi-center phase II study (SAKK 36/06) of single agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2010, 116:2803.
24. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5:671-688.
25. Gupta M., Hendrickson A.W., Han J.J., et al. Dual inhibition of mTORC1/mTORC2 induces apoptosis of mantle cell lymphoma by preventing rictor mediated AKTS473 phosphorylation by potentiating AKT2-PHLPP1 association. Blood (ASH Annual Meeting Abstracts) 2010, 116:772.
26. Evangelisti C., Chiarini F., Ricci F., et al. Targeted inhibition of mTORC1 and mTORC2 by the active-site mTOR inhibitors, PP-242 and OSI-027, has cytotoxic effects in T-cell acute lymphoblastic leukemia. ASH Annual Meeting Abstracts 2010, 116:3242.
27. Zeng Z., Shi Y., Tsao T., et al. Targeting mTORC1/2 by a mTOR kinase inhibitor (PP242) induces apoptosis in AML cells under conditions mimicking bone marrow microenvironment. ASH Annual Meeting Abstracts 2010, 116:778.
28. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8:627-644.
29. Gills J.J., Dennis P.A. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009, 11:102-110.
30. Friedman D.R., Davis P.H., Lanasa M.C., et al. Preclinical and interim results of a phase II trial of perifosine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 2010, 116:1842.
31. Petrich A.M., Leshchenko V.V., Kuo P.-Y., Ye B.H., Sparano J.A., Parekh S. Genomic and pathway connectivity analyses identify novel strategies to overcome mTOR inhibitor resistance in DLBCL. ASH Annual Meeting Abstracts 2010, 116:436.
32. Pal S.K., Reckamp K., Yu H., Figlin R.A. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010, 19:1355-1366.
33. Psyrri A., Papageorgiou S., Liakata E., et al. Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res 2009, 15:5724-5732.
34. Lannutti B.J., Meadows S.A., Herman S.E., et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011, 117:591-594.
35. Kahl B., Byrd J.C., Flinn I.W., et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma. ASH Annual Meeting Abstracts 2010, 116:1777.
36. Garlich J.R., Becker M.D., Shelton C.F., et al. Phase I study of novel prodrug dual PI3K/mTOR inhibitor SF1126 in B-cell malignancies. ASH Annual Meeting Abstracts 2010, 116:1783.
37. Fowler N., Sharman J.P., Smith S.M., et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study. Blood (ASH Annual Meeting Abstracts) 2010, 116:964.
38. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010, 10:537-549.
39. Georgakis G.V., Li Y., Younes A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 2006, 135:68-71.
40. Kim Y.S., Alarcon S.V., Lee S., et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009, 9:1479-1492.
41. Roue G., Perez-Galan P., Mozos A., et al. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 2010, 117:1270-1279.
42. Richardson P.G., Chanan-Khan A.A., Alsina M., et al. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol 2010, 150:438-445.
43. Wang Y., Trepel J.B., Neckers L.M., Giaccone G. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs 2010, 11:1466-1476.
44. Okawa Y., Hideshima T., Steed P., et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009, 113:846-855.
45. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916.
46. Perez-Galan P., Roue G., Villamor N., Montserrat E., Campo E., Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006, 107:257-264.
47. Weniger M.A. NRF2 at the interface of oxidative and endoplasmic reticulum stress pathways is a critical integrator of bortezomib response in mantle cell lymphoma in vitro and in vivo. Blood 2009, 114:727a.
48. Wang Q., Mora-Jensen H., Weniger M.A., et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A 2009, 106:2200-2205.
49. Wright J.J. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010, 16:4094-4104.
50. Goy A., Bernstein S.H., Kahl B.S., et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009, 20:520-525.
51. Kupperman E., Lee E.C., Cao Y., et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010, 70:1970-1980.
52. Parlati F., Lee S.J., Aujay M., et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009, 114:3439-3447.
53. Arastu-Kapur S., Shenk K., Parlati F., Bennett M.K. Non-proteasomal targets of proteasome inhibitors bortezomib and carfilzomib. ASH Annual Meeting Abstracts 2008, 112:2657.
54. diCapua Siegel D.S., Martin T., Wang M., et al. Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 2010, 116:985.
55. Zhou H.J., Aujay M.A., Bennett M.K., et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009, 52:3028-3038.
56. Potts B.C., Albitar M.X., Anderson K.C., et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 2011, 11:254-284.
57. Macherla V.R., Mitchell S.S., Manam R.R., et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 2005, 48:3684-3687.
58. Chauhan D., Catley L., Li G., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005, 8:407-419.
59. Ruan J., Martin P., Furman R.R., et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2010, 29:690-697.
60. Kahl B.S., Li H., Smith M.R., et al. The VcR-CVAD regimen produces a high complete response rate in untreated mantle cell lymphoma (MCL): first analysis of E1405-a phase II study of VcR-CVAD with maintenance rituximab for MCL. ASH Annual Meeting Abstracts 2009, 114:1661.
61. Dunleavy K., Pittaluga S., Czuczman M.S., et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009, 113:6069-6076.
62. Perez-Galan P., Roue G., Villamor N., Campo E., Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007, 109:4441-4449.
63. Goy A., Ford P., Feldman T., et al. A phase 1 trial of the Pan Bcl-2 family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed/refractory mantle cell lymphoma. ASH Annual Meeting Abstracts 2007, 110:2569.
64. Richardson P.G., Badros A.Z., Jagannath S., et al. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol 2010, 150:428-437.
65. Rao R., Fiskus W., Balusu R., et al. Treatment with histone deacetylase 6-specific inhibitor WT-161 disrupts hsp90 function, abrogates aggresome formation and sensitizes human mantle cell lymphoma cells to lethal ER stress induced by proteasome inhibitor carfilzomib. Blood (ASH Annual Meeting Abstracts) 2010, 116:2856.
66. Rao R., Nalluri S., Kolhe R., et al. Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. Mol Cancer Ther 2010, 9:942-952.
67. Bedford L., Lowe J., Dick L.R., Mayer R.J., Brownell J.E. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov 2011, 10:29-46.
68. Soucy T.A., Smith P.G., Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 2009, 15:3912-3916.
69. Lin J.J., Milhollen M.A., Smith P.G., Narayanan U., Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010, 70:10310-10320.
70. Milhollen M.A., Traore T., Adams-Duffy J., et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010, 116:1515-1523.
71. Shah J.J., Harvey R.D., O'Connor O.A., et al. Phase 1 dose-escalation study of multiple dosing schedules of the investigational drug MLN4924, a Nedd8-activating enzyme inhibitor, in patients with relapsed and/or refractory multiple myeloma or lymphoma. ASH Annual Meeting Abstracts 2010, 116:2801.
72. Jin L., Tabe Y., Kojima K., et al. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett 2010, 299:161-170.
73. Tabe Y., Sebasigari D., Jin L., et al. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res 2009, 15:933-942.
74. Andreeff M., Kojima K., Padmanabhan S., et al. A multi-center, open-label, phase I study of single agent RG7112, a first in class p53-MDM2 antagonist, in patients with relapsed/refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas (CLL/SCLL). ASH Annual Meeting Abstracts 2010, 116:657.
75. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008, 9:47-59.
76. Lessene G., Czabotar P.E., Colman P.M. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008, 7:989-1000.
77. Touzeau C., Dousset C., Bodet L., et al. Rational for the use of a targeted-therapy using ABT-737 in mantle-cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2010, 116:770.
78. Yecies D., Carlson N.E., Deng J., Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010, 115:3304-3313.
79. Wilson W.H., O'Connor O.A., Czuczman M.S., et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010, 11:1149-1159.
80. O'Brien S.M., Claxton D.F., Crump M., et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009, 113:299-305.
81. Balakrishnan K., Burger J.A., Wierda W.G., Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009, 113:149-153.
82. Herishanu Y, Gibellini F, Njuguna N, et al. Activation of CD44, a receptor for extracellular matrix components, protects CLL cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma. In press.
83. Krishnakumar R., Kraus W.L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010, 39:8-24.
84. Annunziata C.M., O'Shaughnessy J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res 2010, 16:4517-4526.
85. Weston V.J., Oldreive C.E., Skowronska A., et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 2010, 116:4578-4587.
86. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
87. Copeland A., Buglio D., Younes A. Histone deacetylase inhibitors in lymphoma. Curr Opin Oncol 2010, 22:431-436.
88. Kawamata N., Chen J., Koeffler H.P. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 2007, 110:2667-2673.
89. Watanabe T., Kato H., Kobayashi Y., et al. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 2010, 101:196-200.
90. Kirschbaum M., Frankel P., Popplewell L., et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011, 29:1198-1203.
91. Heider U., von Metzler I., Kaiser M., et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008, 80:133-142.
92. Paoluzzi L., Scotto L., Marchi E., Zain J., Seshan V.E., O'Connor O.A. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res 2010, 16:554-565.
93. Constantinescu S.N., Girardot M., Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci 2008, 33:122-131.
94. Yared M.A., Khoury J.D., Medeiros L.J., Rassidakis G.Z., Lai R. Activation status of the JAK/STAT3 pathway in mantle cell lymphoma. Arch Pathol Lab Med 2005, 129:990-996.
95. Baran-Marszak F., Boukhiar M., Harel S., et al. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica 2010, 95:1865-1872.
96. Pham L.V., Tamayo A.T., Li C., Bornmann W., Priebe W., Ford R.J. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol Cancer Ther 2010, 9:2026-2036.
97. Younes A., Fanale M.A., McLaughlin P., Copeland A., Zhu J., de Castro Faria S. Phase I study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. Blood (ASH Annual Meeting Abstracts) 2010, 116:2830.
98. Chanan-Khan A.A., Cheson B.D. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008, 26:1544-1552.
99. Habermann T.M., Lossos I.S., Justice G., et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009, 145:344-349.
100. Witzig T.E., Vose J.M., Zinzani P.L., Reeder A., Buckstein R. Durable Responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R/R) aggressive non-Hodgkin's lymphoma (a-NHL): results from an international phase 2 study (CC-5013-NHL-003). Blood 2009, 114:1676a.